URGENT UPDATE: A groundbreaking review from researchers at King’s College London has identified alarming risks associated with commonly prescribed antidepressants, including significant weight gain and cardiovascular issues. This critical study, published in The Lancet, analyzed data from over 58,500 patients and revealed that nearly half of those taking amitriptyline, a widely used tricyclic antidepressant, experienced weight gain within just eight weeks.
The findings highlight an average increase of 9 beats per minute in heart rate and a 5 mmHg rise in systolic blood pressure, escalating stroke risk by 5% and overall mortality by almost 10%. Dr. Toby Pillinger, the study’s senior author, emphasized the prevalence of antidepressants, stating, “While many people benefit from them, some can lead to meaningful changes in weight, heart rate, and blood pressure in a relatively short period.”
Other antidepressants also linked to increased cardiovascular risks include nortriptyline, which elevated heart rates by 13 bpm, and mirtazapine, known for causing notable weight gain. In stark contrast, patients on citalopram, a selective serotonin reuptake inhibitor (SSRI), lost an average of 0.65 kg and showed modest improvements in both blood pressure and heart rate.
With 8.8 million people in England currently prescribed these medications, experts are urging immediate health checks for long-term users. Dr. Prada Nishtala from the University of Bath warned that the actual risks could be “much higher,” as many patients remain on these drugs for extended periods.
While health authorities stress that patients should never discontinue antidepressants without consulting their healthcare provider, the authors of the study call for “shared decision-making” in treatment plans and heightened awareness of the physical side effects.
Dr. Alison Cave, chief safety officer at the MHRA, reassured patients that “all known side effects are clearly outlined” in medicine leaflets. She encouraged anyone with concerns to consult their doctor or report symptoms via the Yellow Card scheme.
This urgent study signals a pressing need for more comprehensive monitoring and communication regarding the impacts of antidepressants, emphasizing the balance between mental health treatment and physical well-being. Readers are encouraged to stay informed and share this critical information with others who may be affected.
